Drug intelligence / Profile preview

9N05

Development stage: Unknown
Lead developer: Weill Cornell Medicine

Overview

9N05: sourced facts only. name: "Among them, 9N05 demonstrated the strongest binding affinity towards CHI3L1, and the Kd value was measured as 202.3 ± 76.6 μM." [PMID:41072798]; target: "Among them, 9N05 demonstrated the strongest binding affinity towards CHI3L1, and the Kd value was measured as 202.3 ± 76.6 μM." [PMID:41072798]; developer: "Department of Radiology, Molecular Imaging Innovations Institute (MI3), Weill Cornell Medicine, NY, NY 10065, USA." [PMID:41072798]

Targets

CHI3L1 (Chitinase-3-like protein 1)

Beyond the preview

Go deeper on 9N05.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 9N05.